Kornimate/medical-research-clean huggingface dataset:
stigma, social support and quality of life

Conditions: HIV Infections

Summary: the primary goal of this observational study is to investigate the relationship between perceived stigma and social support in hiv+ patients. the secondary objective is to measure mental health indicators (depression, anxiety, and stress) and quality of life to assess whether they are affected by the relationship between perceived stigma and social support. the main questions it aims to answer are: * measuring perceived stigma and social support to understand the health status and behaviour of people living with hiv. * monitor the mental state of people living with hiv in order to be able to implement, there where necessary, a psychological support strategy in order to promote proper adherence to treatment and care services. participants will fill out an online cross-sectional survey. the online questionnairesurvey will collect: * sociodemographic and clinical data related to hiv infection, * perceived stigma, * social support, * mental health, * quality of life.


Eligibility criteria:
inclusion criteria: * hiv diagnosis. * being treated at the infectious diseases outpatient clinic of policlinico gemelli in rome. * ongoing antiretroviral therapy. * age \> 18 years. * native italian speaker. * informed consent to participate in the study. exclusion criteria: * absence of an hiv diagnosis. * not being treated at the infectious diseases outpatient clinic of policlinico gemelli in rome. * absence of ongoing antiretroviral therapy. * age \> 18 years. * not being a native italian speaker. * refusal to sign informed consent
study of biomarkers in tissue samples from patients with metastatic colon cancer

Conditions: Colorectal Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this research study is looking at biomarkers in tissue samples from patients with metastatic colon cancer.

objectives: * determine the effect of surgical resection, in terms of physiological stress, on levels of tumor markers such as protein kinase a (pka) expression in patients with metastatic colon cancer. * estimate variation among patients of baseline tumor markers in tumor tissue and sera. * correlate markers in tumor tissues with that in sera in these patients. * establish a tissue bank of these specimens for future studies. outline: biopsy and surgical specimens are obtained before and during standard surgery (patients may have had tumor tissue obtained before study entry and stored). serum samples and tumor tissue are analyzed by immunohistochemistry and western blot. tumor markers (such as pka expression) are determined and marker levels are measured in serum samples and tissues. projected accrual: approximately 30 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of colon cancer * metastatic disease for which surgical resection is indicated * metastatic disease accessible for tissue biopsy or previously biopsied tissue is available patient characteristics: * platelet count ≥ 80,000/mm\^3 * inr ≤ 1.3 * ptt ≤ upper limit of normal * no history of bleeding disorders or abnormal clotting factors * no extrahepatic biliary obstruction prior concurrent therapy: * see disease characteristics

Keywords: stage iv colon cancer recurrent colon cancer
effects of sufentanil on the intraoperative hemodynamics

Conditions: Intraoperative Hypotension

Summary: this study is a randomized, controlled trial. a total of 92 patients will be randomized to receive sufentanil or remifentanil during extracranial-intracranial bypass surgery.


Eligibility criteria:
inclusion criteria: * patients who undergo elective extracranial-intracranial bypass surgery * american society of anesthesiologists grade 1,2,3 * age \> 18 years old exclusion criteria: * refuse to participate to the study * american society of anesthesiologists grade 4 * body mass index \ 35 kg/m2 * allergic history of opioid * pregnant * mao inhibitor user * severe respiratory insufficiency
a phase i trial of tamoxifen and 9-cis-retinoic acid in breast cancer patients

Conditions: Breast Cancer; Breast Neoplasm

Summary: this is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic acid given in combination with tamoxifen. groups of 3 to 6 patients receive oral 9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the regimen. patients continue treatment for up to 28 weeks, with tamoxifen continued after the study if medically appropriate.

this is a phase i study of the combination tamoxifen and 9-cis-retinoic acid in patients with breast cancer. the primary objective of the study is; 1) to determine the maximum tolerated dose of 9-cis-retinoic acid in combination with tamoxifen and to determine the overall and dose limiting toxicities. other objectives are: 2) to determine the effect of tamoxifen on the pharmacokinetics of 9-cis-retinoic acid; 3) to evaluate the anti-tumor activity of this combination therapy within the context of a phase i study; 4) and to determine the expression of surrogate biomarkers of breast carcinogenesis before and after treatment.

Eligibility criteria:
disease characteristics: all patients must have histologically documented diagnosis of stage iii, or iv breast carcinoma. patients with stage iii that has completed chemotherapy: estrogen receptor (er) or progesterone receptor (pr) positive tumor required if premenopausal. either er/pr-positive or -negative tumor allowed if postmenopausal and have received prior chemotherapy. patients may have stage iv with er/pr-positive or -negative tumor. no cns metastases, pseudotumor cereri, or seizures. prior/concurrent therapy: patients who have ecovered from the toxic effects of prior therapy will be eligible. patients with prior tamoxifen will be allowed to participate. at least 3 weeks must have elapsed since the last dose of chemotherapy. patient characteristics: age: 18 and over. sex: men and women. menopausal status: any status. patients must have a performance status of ecog 0-2. patients must have hematopoietic criteria of: anc at least 1,500/mm(3). platelet count at least 90,000/mm(3). patients must have hepatic criteria of: in the absence of tumor involvement: bilirubin no greater than twice normal; sgot no greater than twice normal; alkaline phosphate no greater than twice normal; fasting triglycerides less than 3 times normal. patients must have renal criteria of: serum creatinine no greater than 1.5 mg/dl or; creatinine clearance at least 60 ml/min. other: no allergy to study medications. no nonmalignant systemic disease that would preclude therapy. no second malignancy within 5 years except: curatively treated basal cell skin carcinoma. cervical carcinoma in situ. pregnant women will be excluded. negative pregnancy test required within 7 days prior to entry. adequate contraception required for 4 weeks prior to, during, and for 1 year after study. patients must give informed consent. patients who are poor medical or psychiatric risks will be eligible.

Keywords: retinoids biomarkers
antidepressant monotherapy on depressive and anxiety symptom in chinese patients

Conditions: Adverse Drug Reaction; Anxiety Disorders and Symptoms

Summary: the primary objective is to evaluate the improvement of antidepressant monotherapy on depressive and anxiety symptom in chinese patients who meet diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria for the comorbidity of major depressive disorder (mdd) and generalized anxiety disorder (gad)

to evaluate the improvement of the quality of life of antidepressant monotherapy on chinese patients who meet dsm-5 criteria for the comorbidity of mdd and gad. to monitor adverse events (aes) and serious adverse events (saes) of antidepressant monotherapy

Eligibility criteria:
inclusion criteria: 1. first episode outpatients in department of psychiatry, aged 18-65 years 2. comorbidity of mdd and gad according to dsm-5 criteria hamilton depression score (hamd) of ≥18 at screening 3. hama≥14 at screening 4. medically stable 5. provision of written, informed consent. exclusion criteria: 1. suicide ideation 2. use antidepressants within at least 14 days before study begin 3. substance or alcohol dependence at enrolment (except dependence in full remission, and except for caffeine or nicotine dependence) 4. opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse within 4 weeks prior to enrolment 5. unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension, renal or hepatic dysfunction, cerebrovascular disease ) as judged by the investigator 6. women in pregnancy or lactation 7. medical conditions that would affect absorption, distribution, metabolism or excretion of study treatment. 8. medical history with seizure disorder, except for febrile convulsion 9. participation in another clinical study within 4 weeks (or longer time according to the local requirement) 10. receive electroconvulsive therapy (ect) before study begin
a study of tirzepatide (ly3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes

Conditions: Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D

Summary: we are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (t2d). the study will last about 56 weeks and include up to 12 visits.


Eligibility criteria:
inclusion criteria: all participants with or without diabetes: * have a body mass index (bmi) ≥27 kilogram/square meter (kg/m²) at screening * diagnosed with chronic kidney disease (ckd) * has an estimated glomerular filtration rate (egfr) ≥25 to ≤60 ml/min/1.73 m² or egfr ≥25 to ≤75 ml/min/1.73 m² if urine albumin-to-creatinine ratio (uacr) \>30 milligram/gram (mg/g) * have been receiving an angiotensin-converting enzyme (ace) or angiotensin ii receptor blockers (arb) that is considered the maximal appropriate dose by the investigator for treatment of chronic kidney disease or hypertension (unless the participant has low blood pressure or hypotension) participants without diabetes: * have hemoglobin a1c (hba1c) \<6.5% at screening participants with type 2 diabetes: * have been diagnosed at least 180 days prior to screening * have hba1c ≤9.5% at screening exclusion criteria: all participants: * have a self-reported change in body weight \>5 kilogram (kg) within 90 days prior to screening. * have a prior or planned surgical treatment for obesity * have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 180 days * have egfr \<25 ml/min/1.73m² calculated by using creatinine-based chronic kidney disease epidemiology collaboration (ckd-epi) equations, as determined by central laboratory at screening. * have a history of unstable or rapidly progressing renal disease according to investigator judgment * have a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect gi motility) * have had a history of chronic or acute pancreatitis participants with t2d: * have history of proliferative diabetic retinopathy or diabetic macular edema or non-proliferative diabetic retinopathy that requires acute treatment. * have been diagnosed with type 1 diabetes (t1d) or have history of ketoacidosis or hyperosmolar state/coma
preventive application of letrozole decrease incidence of early onset of ohss

Conditions: Ovarian Hyperstimulation Syndrome

Summary: letrozole is one kind of aromatase inhibitors which may have effect on decrease estrogen in luteal phase and inhibit the luteal function of ovary. in 2009, letrozole was reported as one candidate for the treatment or prevention of ovarian hyperstimulation syndrome.

letrozole was proved to be effective in decreasing the estradiol level of luteal phase after ovum picked up. in this randomized controlled study, investigators try to observe the effectiveness of letrozole on decreasing the incidence of early ovarian hyperstimulation syndrome and vascular epithelium growth factor level of women with high ovarian hyperstimulation syndrome risks.

Eligibility criteria:
inclusion criteria: * infertile women undergoing ivf treatment with more than 25 oocytes collected. exclusion criteria: * letrozole contraindications,e.g. severe hepatic and renal dysfunction

Keywords: letrozole ovarian hyperstimulating syndrome
pilot tms in mild tbi

Conditions: Persistent Post Concussive Headache; Mild Traumatic Brain Injury

Summary: persistent post-concussive symptoms (ppcs) involve an array of physical, cognitive, and behavioral symptoms lasting more than a month after mild traumatic brain injury (mtbi). 34-44% of people with mtbi or concussion present with a considerable burden of ppcs 3-6 months after injury. there is currently no standardized treatment for ppcs, nor fda approved medication for any neuropsychiatric or neurocognitive symptoms associated with mtbi. transcranial magnetic stimulation (tms) shows promise as a treatment for ppcs; however, the current one-size-fits-all approach does not address the heterogeneity of symptoms. we propose utilization of resting state functional mri (rs-fmri) guided rtms to target personalized brain networks burdened with ppcs.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of mtbi at least 4 weeks prior but not exceeding 12 months prior to the time of screening 2. age 18-65 years at the time of mtbi 3. high burden of post concussive symptoms at time of screening, as measured by symptoms questionnaire (pcss) ≥35\* exclusion criteria: 1. inability to tolerate imaging; contraindication of imaging due to implants or metal 2. seizure disorder, active alcohol or substance use disorder 3. inability to speak and read english 4. anything else that, in the opinion of the pi/study physician, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study. 5. subject is pregnant or breast feeding 6. subject has participated in a clinical interventional trial in the last 3 months

Keywords: transmagnetic stimulation functional mri guided theta burst stimulation intermittent theta burst stimulation
hemo filtration reinfusion (hfr) clearance efficiency towards p-bound toxins and effects on inflammatory and endothelial damage markers

Conditions: Inflammation

Summary: the aim of this study is to compare purification efficiency of hfr in terms of clearance of protein-bound toxins and the effects on markers of inflammation and endothelial damage, in comparison to hf-hd and ol-hdf.

protein-bound uremic toxins are poorly removed by current dialysis techniques because of their size, which is larger than the pore size of dialysis membranes available in the market. these protein-bound uremic toxins have emerged as important risk factors for progression of ckd, as well as for cardiovascular disease. several studies have demonstrated that protein-bound uremic toxins induce vascular inflammation, endothelial dysfunction and vascular calcification. in dialysis patients, serum concentrations of p-cresyl sulphate and indoxyl sulphate are approximately 17 and 54 times higher, respectively, than in healthy subjects. because these toxins are bound to proteins, only a 30% or less is removed efficiently by hemodialysis. traditional renal replacement therapies depend upon diffusion and convection for solute clearances and the use of an adsorbent in combination with dialysis membranes may be a new therapeutic option to increase removal rate of these uremic protein-bound toxins. hfr technique uses a dual dialyzer with a resin between chambers. the first chamber is a high-flux membrane where convective process takes place. the ultrafiltrate obtained from this first chamber passes through the cartridge and is reinfused before the second chamber, a low-flux membrane, where diffusive process is performed. in hfr, adsorption and haemodiafiltration are attached, using ultrafiltrate as a replacement fluid and being capable of theoretically removing most medium and high molecular weight uremic toxins. a potential benefit has been regarded for toxicity, biocompatibility, tolerance, and preservation of essential elements such as albumin, vitamins, amino acids or growth factors. an improvement on oxidative stress has also been described in hfr.

Eligibility criteria:
inclusion criteria: * stable patients on hemodialysis for al least 3 month * older than 18 year old * dialyzed at least for two months with a high-flux membrane permeability * arteriovenous fistula with high blood flow (\> 350 ml / min) exclusion criteria: * active neoplasia * positive viral markers (hbsag, anti-hcv and hiv), * clinical signs of active infection and/or inflammation, * albumin \< 3.5 g/dl.
pilot trial: bioavailability animal vs. plant protein drink

Conditions: Nutrition, Healthy; Leucine Sensitivity

Summary: a pilot study is being conducted to compare a new plant-based protein drink to commercially available animal-based protein drinks. the goal is to assess if the plant-based drink delivers amino acids to the bloodstream as effectively as the animal-based drinks, potentially offering a viable option for those on plant-based diets. the study will involve approximately 12 healthy adults aged 18-40. each participant will try all three drinks (the new plant-based drink, a commercial animal-based drink, and another animal-based recipe) on separate days in a randomized order. before and after (30, 60, and 90 minutes) consuming each drink, a small blood sample will be drawn to measure amino acid levels (leucine). by comparing the results, the investigators hope to determine if the plant-based drink can match the effectiveness of animal-based protein drinks in delivering essential nutrients. this research could contribute to the development of sustainable and nutritious plant-based protein alternatives.


Eligibility criteria:
inclusion criteria * gender: male and female * age: 18-40 years * signed written informed consent exclusion criteria * smoking history * cardiovascular diseases * bmi \> 35 kg/m2 * caffeine consumption \< 1 day before the study participation * allergies: soy, peas, milk, lactose, fructose * high intensity exercise \<2 days before study participation

Keywords: leucin plant-based animal-based bioavailability
efficacy and safety of 1 g vs 2 g per hour intravenous maintenance dose of mgso4 in women with severe pre-eclampsia

Conditions: Severe Preeclampsia

Summary: preeclampsia is commonly viewed as one of the hypertensive pregnancy disorders, which cover a spectrum of clinical presentations from chronic hypertension ( hypertension occurring prior to 20 weeks of gestation) and gestational hypertension (hypertension occurring after 20 weeks of gestation) to more severe forms, including preeclampsia, eclampsia (its convulsive form), and hellp syndrome (hemolysis, elevated liver enzyme s, and low platelets)

treatment for patients who have developed preeclampsia or eclampsia mainly consists of control of hypertension, magnesium sulphate for prevention of eclampsia and convulsions, and planning for delivery. magnesium sulfate has been used to prevent eclamptic convulsion since 1925, its efficacy was confirmed by a large randomized controlled trial in 2002. eclampsia could be prevented in more than 50% after magnesium sulfate administration . the world health organization recommended magnesium sulfate as the most effective, safe, and low-cost drug for the prevention of seizure in severe preeclampsia and eclampsia . the recommended dose of magnesium sulfate is 4 to 6 gram intravenous loading dose, followed by maintenance intravenous drip at the rate of 1 to 2 gram per hour . although different magnesium sulfate regimens have been tested, two dosing regimens are internationally recommended and widely used. the pritchard regimen is a predominantly intramuscular regimen given as a loading dose of 4 g intravenously , and 5 g intramuscular into each buttock followed by a maintenance dose of 5 g intramuscular every 4 hours. this regimen is popular in resource-limited settings where intravenously administration of magnesium sulfate may not be feasible. however, it is associated with pain and a higher risk of infection at the injection site. the zuspan regimen is given as a 4 gram intravenously loading dose followed by continuous intravenously infusion of 1 gram per hour. either 1 gram or 2 gram maintenance dose of magnesium sulphate has been reported to reduce the development of eclampsia. randomized controlled trials offering direct comparison between these 2 doses are lacking.

Eligibility criteria:
inclusion criteria: * pregnant women admitted to women health hospital with a diagnosis of severe pre-eclampsia exclusion criteria: * 1- women with non-proteinuric hypertension, 2- severe renal impairment 3- myasthenia gravis 4- high amount of magnesium in blood 5- low or high amount of calcium in blood 6- myocardial damage, diabetic coma, heart block
low-energy laser applications in patients with juvenile idiopathic arthritis

Conditions: Juvenile Idiopathic Arthritis; Rheumatic Diseases; Chronic Knee Pain; Fatigue; Muscle Weakness; Polyarticular JCA

Summary: this study endeavored to evaluate the auxiliary effect of low-energy laser therapy (llt) on pain, muscle performance, fatigue, and functional ability in children with juvenile idiopathic arthritis (jia). sixty patients with jia were randomly allocated to the llt group (n = 30, received llt in addition to the standard exercise program) or the control group (n = 30, received standard exercise program only). both groups were assessed for pain intensity, muscle performance, fatigue perception, and functional status.

sixty patients with jia were recruited from the physical therapy outpatient clinic of college of applied medical sciences, prince sattam bin abdulaziz university, and the pediatric rheumatology clinic, king khalid hospital, al-kharj, saudi arabia. the study included patients who had a confirmed diagnosis of polyarticular jia (according to the criteria set forth by the international league of associations for rheumatology), aged 8-16 years, identified being stable cases, and did not participate in a regular exercise program (in the past six months). patients who had fixed deformities, a history of joint surgery, or whose radiological investigations revealed erosive changes of bone, ankylosing, or fractures were excluded. outcome measures 1. pain intensity: measures through the visual analogue scale 2. muscle performance: represented by the peak concentric torque of the right and left quadriceps muscle and measured through an isokinetic dynamometer. 3. fatigue perception: tested by the pediatric quality of life inventory multidimensional fatigue scale (pedsql-mfs) 4. functional status: the functional status was quantified using the cross-cultural validated version of the childhood health assessment questionnaire (chaq). patients in the control and llt group received a 40-minute exercise program, three times a week, for three months in succession. patients in the llt group additionally underwent an articular application of llt on the knee joint, each session before exercises (eight points on each knee, 30 seconds irradiation for each point, with a total irradiation dose of eight minutes per session. the treatment was conducted by two experienced pediatric physical therapists.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of jia * polyarticular onset of jia with bilateral involvement of the knee joint * age between 8 and 16 years * stable conditions (i.e., receive stable doses of medications in the past three months) * not participating in a regular exercise program in the past six months exclusion criteria: * fixed deformities * history of joint surgery * ankylosing or fractures * bone destruction (erosive changes of the knee joint)